Sponsored by:
A report by The Economist Intelligence Unit
REDUCING THE BURDEN:
The economic and social
costs of lung cancer in ItalyREDUCING THE BURDEN
THE ECONOMIC AND SOCIAL COSTS OF LUNG CANCER IN ITALY
2 Introduction
4 Executive summary
6 Chapter 1:Assessing the burden: Who is affected, and how
13 Chapter 2:Reducing the burden: Prevention and treatment
19 Chapter 3: Comparing strategies: The fght against lung cancer
23 Conclusion
CONTENTSREDUCING THE BURDEN
THE ECONOMIC AND SOCIAL COSTS OF LUNG CANCER IN ITALY
INTRODUCTION
Lung cancer is one of the world’s deadliest diseases. In 2015 it was believed responsible
for an estimated 280,000 deaths in the European Union, or 20% of all cancer deaths.1
In men, lung cancer is the most common kind of fatal cancer. Among women, it is the
second most common kind of fatal cancer.2
In Italy, the picture mirrors the global trend. Lung cancer is the biggest killer of men and is
tied with colorectal cancer for the most deaths in women. Moreover, the impact of lung
cancer in Italy has been increasing over the past two decades. Deaths from lung cancer
were above 35,000 in 2013, up from fewer than 31,000 in 1990. Lung cancer is expected
to be diagnosed in 40,000 cases in 2016, according to the Italian Association of Medical
Oncology (AIOM) in its publication “I numeri del Cancro in Italia 2016” (Cancer numbers
in Italy 2016). The number of disability-affected life years (DALYs), or years of life lost due
to lung cancer, rose above 607,000 in 2013, after falling below 600,000 in 2010.3
With this as background, The Economist Intelligence Unit undertook research to assess
the economic and social impact of lung cancer in Italy and to compare policy
approaches aimed at reducing that impact, including a comparison between Italian
strategies and approaches used in neighbouring countries.
Reducing the burden: The economic and social costs of lung cancer in Italy
presents
the results of this research. This white paper was written by The Economist Intelligence
Unit (EIU) and sponsored by Roche. Itis based on desk research and in-depth interviews
with 15 experts in the topic. The EIU would like to thank the following participants in the
interview programme (listed alphabetically) for their time and insights:
l Federico Cappuzzo, director of medical oncology, Ospedale Santa Maria delle Croci,
Ravenna
l Christos Chouaid, head of thoracic oncology, Centre Hospitalier Intercommunal,
Créteil, France
l Francesco De Lorenzo, president of the European Cancer Patient Coalition, and
president of the Italian Federation of Volunteer-based Cancer Organisations
l Mina Gaga, president-elect, European Respiratory Society
l Marina Garassino, medical consultant, Medical Oncology Division of the National
Cancer Institute of Milan
l G Scott Gazelle, professor of radiology, Harvard Medical School, and professor in the
department of health policy management, Harvard School of Public Health
l Claudio Jommi, professor of public management and policy, Centre for Research on
Health and Social Care Management, Graduate Business School of Bocconi University,
Milan
1 Malvezzi, M, Carioli, G.
et al
.,
“European cancer mortality predictions
for the year 2016 with focus on
leukaemias”
Annals of Oncology
, Vol
27, January 26th 2016,pp. 725-731.
http://annonc.oxfordjournals/
content/27/4/725.long
2 World Health Organisation, 10 Facts
on Cancer. Available at:
who.int/features/factfiles/cancer/
facts/en/index4.html
3 Institute for Health Metrics and
Evaluation,
Global Burden of Disease
,
2013.REDUCING THE BURDEN
THE ECONOMIC AND SOCIAL COSTS OF LUNG CANCER IN ITALY
l Carlo La Vecchia, associate professor of epidemiology, University of Milan, and head
of the laboratory of epidemiology, Mario Negri Institute for Pharmacological Research,
Milan
l Jessica Menis, clinical research physician, European Organisation for Research and
Treatment of Cancer
l Silvia Novello, professor of medical oncology, San Luigi Hospital at the University of
Turin, and president, Women against Lung Cancer in Europe
l Carmine Pinto, president of the Italian Association of Medical Oncology (AIOM)
l Georgio Scagliotti, professor of medical oncology, University of Turin, and president,
International Association for the Study of Lung Cancer
l Richard Sullivan, director, Institute of Cancer Policy and King’s Health Partners
Comprehensive Cancer Centre, King’s College London
l Kostas Syrigos, head of the oncology department, School of Medicine, University of
Athens
l Stefania Vallone, president, Lung Cancer Europe, Italy
The Economist Intelligence Unit bears sole responsibility for the content of this report. The
fndings and views expressed here do not necessarily refect the views of the sponsor.
Andrea Chipman was the author of this report, and Aviva Freudmann was the editor.
。。。以上简介无排版格式，详细内容请下载查看